摘要
【目的】探讨对血利钠肽前体（NT-proBNP）浓度异常的血液透析患者进行干预治疗，对预防心血管并发症的作用研究。【方法】收集血液透析患者，利钠肽前体超过450ng／L 115例。分为两组，对照组50例，常规血液透析治疗；干预组65例，在对照组基础上加抗心衰治疗。观察两组首次严重心血管事件。【结果】干预组经抗心衰治疗后NT-proBNP浓度较干预前明显下降，也低于对照组，差异有显著性（P〈0．05）。共有37例患者因心血管原因死亡（32．2％），死亡患者的血浆NT—proBNP水平较非致死性心血管事件患者的高，差异有显著性（P〈0．05）。非致死心血管事件发生率干预组26例（40％，26／65），对照组35例（70％，35／50），两组间差异有显著性（P〈0．01），但死亡率差异无显著性（P〉0．05）。发生首次严重心血管事件的患者的血浆NT—proBNP水平相比，差异无显著性（P〉0．05）。【结论】对血液透析患者利钠肽前体异常者予以抗心衰治疗，能降低心血管事件的发生。
[Objective] To explore the effect of intervention therapy on the prevention of cardiovascular complications in hemodialysis patients with abnormal natriuretic peptide precursor（NT proBNP） level. [Methods] In 115 hemodialysis patients, NT-proBNP level was beyond 450ng/L. All patients were divided into control group（ n = 50） and intervention group（ n =65）. The control group received conventional hemodialysis treatment. The intervention group received anti-heart failure therapy based on conventional hemodialysis treatment. The first serious cardiovascular events were observed. [Results]Compared with before the intervention, NT-proBNP concentration in the intervention group after the anti heart failure treatment decreased significantly, and was lower than that in the control group, and the difference was significant （ P 〈0.05）. A total of 37 patients（32.2 %） died of cardiovascular events, and their plasma NT-proBNP level was higher than that of pa tients with non-fatal cardiovascular events, and the difference was significant （ P 〈0.05）. The incidence of non-fatal cardiovascular events in the intervention group and control group was 40% （26/25） and 70% （35/ 50）, and the difference between the two groups was significant （ P 〈0.01）, but the mortality difference was not statistically significant （ P 〉0.05） . The plasma NT-proBNP level in patients with first serious cardiovascular events had no significant difference （ P 〉0.05）. [Conclusion] Anti-heart failure therapy for hemodialysis patients with abnormal NT-proBNP is effective and can reduce cardiovascular complications.
出处
《医学临床研究》
CAS
2010年第4期623-625,共3页
Journal of Clinical Research
关键词
血液透析
心血管疾病/并发症
心钠素
hemodialysis
cardiovascular diseases/CO atrial natriuretic factor
